Seclidemstat mesylate is under clinical development by Salarius Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Seclidemstat mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seclidemstat mesylate overview
Seclidemstat (SP-2577) is under development for the treatment of relapsed and refractory Ewing’s sarcoma, prostate cancer, ovarian cancers including small cell carcinoma of the ovary hypercalcemic type (SCCOHT) and ovarian clear cell carcinoma (OCCC), pancreatic cancer, cervical cancer, endometrioid endometrial carcinoma (EEC), melanoma, colorectal cancer, myelodysplastic syndromes, chronic myelomonocytic leukemia, non-Ewing’s sarcomas, glioblastoma, hematological cancers, acute myelocytic leukemia (AML) (hematologic cancer), small cell lung cancer and other solid tumors. It is a small molecule which is administered through oral route in the form of tablet. The drug candidate acts by targeting lysine-specific histone demethylase 1 (LSD-1). The drug candidate was also under development for the treatment of triple-negative breast cancer (TNBC), non-small cell lung cancer, and myxoid liposarcoma, FET-rearranged sarcomas.
Salarius Pharmaceuticals overview
Salarius Pharmaceuticals is a biotechnology company that develops drugs for pediatric and other cancers. It investigates its lead compound Seclidemstat for the treatment of ewing sarcoma, myxoid liposarcoma, FET-rearranged sarcomas, hematologic and gynecological cancers. The company also evaluates SP-3164 and NCE 2nd generation LSD1i (lysine specific demethylase 1) programs against hematological and solid tumors. The company carries out targeted protein inhibition (TPI) and targeted protein degradation (TPD). Salarius Pharmaceuticals is headquartered in Houston, Texas, the US.
For a complete picture of Seclidemstat mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
